| Symbol | CLDI |
|---|---|
| Name | CALIDI BIOTHERAPEUTICS, INC. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | 4475 EXECUTIVE DRIVE, SAN DIEGO, CA 92121 |
| Telephone | 858-794-9600 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | None |
New Form DEFA14A - Calidi Biotherapeutics, Inc. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001493152-26-019636 <b>Size:</b> 2 MB
Read moreCalidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
Read moreNew Form PRE 14A - Calidi Biotherapeutics, Inc. <b>Filed:</b> 2026-04-17 <b>AccNo:</b> 0001493152-26-017935 <b>Size:</b> 1 MB
Read moreCalidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
Read moreCalidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy
Read moreCalidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
Read moreCalidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
Read moreNew Form SCHEDULE 13D - Calidi Biotherapeutics, Inc. <b>Filed:</b> 2026-03-31 <b>AccNo:</b> 0002109116-26-000004 <b>Size:</b> 6 KB
Read more(30% Negative) CALIDI BIOTHERAPEUTICS, INC. (CLDI) Reports Q1 2026 Financial Results
Read moreCalidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights
Read more